Tyrosine kinases: the molecular switch for inflammasome activation

Cellular and Molecular Immunology

Volumn 11, Issue 2, 2014, Pages 129-131

  Laudisi, Federica ^a   Viganò, Elena ^a   Mortellaro, Alessandra ^a  

^a AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; FOSTAMATINIB; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 9; PRALNACASAN; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1;

CYTOKINE RELEASE; HUMAN; INFLAMMATORY CELL; LISTERIA MONOCYTOGENES; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOTE; OSTEOARTHRITIS; PERITONITIS; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS;

ANIMALS; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; INFLAMMASOMES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-TYROSINE KINASES;

EID: 84895535697     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2014.4     Document Type: Note

References (10)

1. Martinon F, Burns K, Tschopp J. The inflammasome: A molecular platform triggering activatio of inflammatory caspases and processing of proIL-1beta. Mol Cell 2002; 10: 417-426
2. Zambetti LP, Laudisi F, Licandro G, Ricciardi-Castagnoli P, Mortellaro A. The rhapsody of NLRPs: Master players of inflammation. a lot more. Immunol Res 2012; 53: 78-90
3. Hara H, Tsuchiya K, Kawamura I, Fang R, Hernandez-Cuellar E, Shen Y et al. Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity. Nat Immunol 2013; 14: 1247-1255
4. Miao EA, Rajan JV, Aderem A. Caspase-1-induced pyroptotic cell death. Immunol Rev 2011; 243: 206-214
5. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: Host cell death and inflammation. Nat Rev Microbiol 2009; 7: 99-109
6. Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 2013; in press.
7. Rudolphi K, Gerwin N, Verzijl N, van der Kraan P, van den Berg W. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 2003; 11: 738-746
8. Grimminger F, Schermuly RT, Ghofrani HA. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov 2010; 9: 956-970
9. Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011; 63: 337-345
10. Flight MH. Deal watch: High hopes for oral SYK inhibitor in rheumatoid arthritis. Nat Rev Drug Discov 2012; 11: 10